{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": "FlublokPI",
  "verified_evidence": [
    {
      "id": 1,
      "quote": "Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by GlaxoSmithKline) as an active control [see Clinical Studies (14)]. The safety analysis population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine recipients.",
      "supports_claim": true,
      "explanation": "The quote appears on page 3 of the document, with only minor formatting and OCR differences. The document states: 'Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by GlaxoSmithKline) as an active control [see Clinical Studies (14)]. The safety analysis population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine recipients.' This matches the quote in all substantive details, including the study number, age group, randomization, comparator (Fluarix Quadrivalent), manufacturer, and the numbers of recipients in each group.. The quote directly supports the claim. It explicitly states that Flublok Quadrivalent was evaluated in a trial (Study 6) where it was compared against Fluarix Quadrivalent, a standard-dose quadrivalent vaccine, in subjects 50 years and older. The details provided confirm a head-to-head evaluation, as asserted in the claim.",
      "presence_explanation": "The quote appears on page 3 of the document, with only minor formatting and OCR differences. The document states: 'Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by GlaxoSmithKline) as an active control [see Clinical Studies (14)]. The safety analysis population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine recipients.' This matches the quote in all substantive details, including the study number, age group, randomization, comparator (Fluarix Quadrivalent), manufacturer, and the numbers of recipients in each group.",
      "support_explanation": "The quote directly supports the claim. It explicitly states that Flublok Quadrivalent was evaluated in a trial (Study 6) where it was compared against Fluarix Quadrivalent, a standard-dose quadrivalent vaccine, in subjects 50 years and older. The details provided confirm a head-to-head evaluation, as asserted in the claim.",
      "original_relevance": "This quote explicitly states that Flublok Quadrivalent was evaluated in a trial (Study 6) where it was directly compared against Fluarix Quadrivalent, confirming the pivotal head-to-head evaluation."
    },
    {
      "id": 2,
      "quote": "The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol defined ILI due to any strain of influenza. Attack rates and relative vaccine efficacy (rVE), defined as 1 [Attack rate Flublok Quadrivalent Attack Rate Comparator], were calculated for the total efficacy population (n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5). ... Comparator, Fluarix Quadrivalent, manufactured by GlaxoSmithKline (n=4489).",
      "supports_claim": true,
      "explanation": "The quote appears on page 4 of the document. The text states: 'The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol defined ILI due to any strain of influenza. Attack rates and relative vaccine efficacy (rVE), defined as 1 [Attack rate Flublok Quadrivalent Attack Rate Comparator], were calculated for the total efficacy population (n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5).' Immediately after, it specifies: 'Comparator, Fluarix Quadrivalent, manufactured by GlaxoSmithKline (n=4489).' The factual content, numbers, and technical details are preserved and match the quote to verify.. The quote directly supports the claim. It explicitly states that Study 6 evaluated Flublok Quadrivalent against Fluarix Quadrivalent (a standard-dose quadrivalent vaccine) as the comparator. The description of the study design, endpoints, and comparator vaccine matches the claim exactly, with no inference required.",
      "presence_explanation": "The quote appears on page 4 of the document. The text states: 'The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol defined ILI due to any strain of influenza. Attack rates and relative vaccine efficacy (rVE), defined as 1 [Attack rate Flublok Quadrivalent Attack Rate Comparator], were calculated for the total efficacy population (n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5).' Immediately after, it specifies: 'Comparator, Fluarix Quadrivalent, manufactured by GlaxoSmithKline (n=4489).' The factual content, numbers, and technical details are preserved and match the quote to verify.",
      "support_explanation": "The quote directly supports the claim. It explicitly states that Study 6 evaluated Flublok Quadrivalent against Fluarix Quadrivalent (a standard-dose quadrivalent vaccine) as the comparator. The description of the study design, endpoints, and comparator vaccine matches the claim exactly, with no inference required.",
      "original_relevance": "This quote describes the design of Study 6, specifying that Flublok Quadrivalent was compared to Fluarix Quadrivalent for efficacy, directly supporting the claim."
    },
    {
      "id": 3,
      "quote": "Abbreviations: rtPCR=reverse transcriptase polymerase chain reaction; Comparator=U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent, manufactured by GlaxoSmithKline; n=number of influenza cases; N=number of subjects in treatment group; RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) \u00d7 100]. *Study 6 is registered as NCT02285998.",
      "supports_claim": true,
      "explanation": "The quote appears on page 4 of the document, in the following form: 'Abbreviations: rtPCR=reverse transcriptase polymerase chain reaction; Comparator=U.S.licensed quad rival ent in activated influenza vaccine, Fluarix Quad rival ent, manufactured by GlaxoSmithKline; n=number of influenza cases; N=number of subjects in treatment group; RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) \u00d7 100]. *Study 6 is registered as NCT02285998.' The wording and content are semantically equivalent to the quote to verify, with only minor formatting differences (e.g., 'quad rival ent' instead of 'quadrivalent' due to OCR, and spacing differences). All technical content and facts are preserved.. The quote explicitly states that in Study 6, the comparator for Flublok Quadrivalent was 'U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent, manufactured by GlaxoSmithKline.' This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine). The quote also references the study registration number (NCT02285998), further confirming the context. No inference is required; the quote directly substantiates the claim.",
      "presence_explanation": "The quote appears on page 4 of the document, in the following form: 'Abbreviations: rtPCR=reverse transcriptase polymerase chain reaction; Comparator=U.S.licensed quad rival ent in activated influenza vaccine, Fluarix Quad rival ent, manufactured by GlaxoSmithKline; n=number of influenza cases; N=number of subjects in treatment group; RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) \u00d7 100]. *Study 6 is registered as NCT02285998.' The wording and content are semantically equivalent to the quote to verify, with only minor formatting differences (e.g., 'quad rival ent' instead of 'quadrivalent' due to OCR, and spacing differences). All technical content and facts are preserved.",
      "support_explanation": "The quote explicitly states that in Study 6, the comparator for Flublok Quadrivalent was 'U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent, manufactured by GlaxoSmithKline.' This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine). The quote also references the study registration number (NCT02285998), further confirming the context. No inference is required; the quote directly substantiates the claim.",
      "original_relevance": "This quote clarifies that in Study 6, the comparator for Flublok Quadrivalent was Fluarix Quadrivalent, providing further direct evidence that these two vaccines were evaluated against each other in the pivotal trial."
    },
    {
      "id": "comp_1",
      "quote": "Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by GlaxoSmithKline) as an active control [see Clinical Studies (14)]. The safety analysis population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine recipients. The mean age of participants was 62.7 years. Overall, 58% of subjects were female, 80% white/Caucasian, 18% black/African American, 0.9% American Indian/Alaskan Native, 0.2% Native Hawaiian/Pacific Islander, 0.5% Asian, 1.4% other racial groups, and 5% of Hispanic/Latino ethnicity.",
      "supports_claim": true,
      "explanation": "The quote appears in the document on page 3: 'Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by GlaxoSmithKline) as an active control [see Clinical Studies (14)]. The safety analysis population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine recipients. The mean age of participants was 62.7 years. Overall, 58% of subjects were female, 80% white/Caucasian, 18% black/African American, 0.9% American Indian/Alaskan Native, 0.2% Native Hawaiian/Pacific Islander, 0.5% Asian, 1.4% other racial groups, and 5% of Hispanic/Latino ethnicity.' The factual content, numbers, and technical details match the quote to verify.. The quote directly supports the claim. It explicitly states that Study 6 (the pivotal trial) enrolled subjects 50 years and older and randomized them to receive either Flublok Quadrivalent or Fluarix Quadrivalent (the standard-dose comparator), confirming that Flublok was evaluated against Fluarix in the pivotal trial. No inference is required; the information is explicit and complete.",
      "presence_explanation": "The quote appears in the document on page 3: 'Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by GlaxoSmithKline) as an active control [see Clinical Studies (14)]. The safety analysis population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine recipients. The mean age of participants was 62.7 years. Overall, 58% of subjects were female, 80% white/Caucasian, 18% black/African American, 0.9% American Indian/Alaskan Native, 0.2% Native Hawaiian/Pacific Islander, 0.5% Asian, 1.4% other racial groups, and 5% of Hispanic/Latino ethnicity.' The factual content, numbers, and technical details match the quote to verify.",
      "support_explanation": "The quote directly supports the claim. It explicitly states that Study 6 (the pivotal trial) enrolled subjects 50 years and older and randomized them to receive either Flublok Quadrivalent or Fluarix Quadrivalent (the standard-dose comparator), confirming that Flublok was evaluated against Fluarix in the pivotal trial. No inference is required; the information is explicit and complete.",
      "original_relevance": "This quote explicitly states that Study 6 randomized subjects to receive either Flublok Quadrivalent or Fluarix Quadrivalent (the standard-dose comparator), directly supporting the claim that Flublok was evaluated against Fluarix in the pivotal trial."
    },
    {
      "id": "comp_2",
      "quote": "The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol defined ILI due to any strain of influenza. Attack rates and relative vaccine efficacy (rVE), defined as 1 [Attack rate Flublok Quadrivalent Attack Rate Comparator], were calculated for the total efficacy population (n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5). Comparator, Fluarix Quadrivalent, manufactured by GlaxoSmithKline (n=4489).",
      "supports_claim": true,
      "explanation": "The quote appears on page 4 of the document. The text states: 'The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol defined ILI due to any strain of influenza. Attack rates and relative vaccine efficacy (rVE), defined as 1 [Attack rate Flublok Quadrivalent Attack Rate Comparator], were calculated for the total efficacy population (n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5). Comparator, Fluarix Quadrivalent, manufactured by GlaxoSmithKline (n=4489).' This matches the quote to verify, with only minor formatting differences (e.g., line breaks, punctuation), but all facts, numbers, and technical content are preserved.. The quote explicitly states that Study 6 evaluated Flublok Quadrivalent against Fluarix Quadrivalent (the comparator), and provides the sample sizes for each group. This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine). No inference is required; the information is explicit.",
      "presence_explanation": "The quote appears on page 4 of the document. The text states: 'The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol defined ILI due to any strain of influenza. Attack rates and relative vaccine efficacy (rVE), defined as 1 [Attack rate Flublok Quadrivalent Attack Rate Comparator], were calculated for the total efficacy population (n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5). Comparator, Fluarix Quadrivalent, manufactured by GlaxoSmithKline (n=4489).' This matches the quote to verify, with only minor formatting differences (e.g., line breaks, punctuation), but all facts, numbers, and technical content are preserved.",
      "support_explanation": "The quote explicitly states that Study 6 evaluated Flublok Quadrivalent against Fluarix Quadrivalent (the comparator), and provides the sample sizes for each group. This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine). No inference is required; the information is explicit.",
      "original_relevance": "This quote details the design of Study 6, specifying that Flublok Quadrivalent was compared to Fluarix Quadrivalent as the comparator, and that efficacy was measured between these two vaccines, directly affirming the claim."
    }
  ],
  "verification_stats": {
    "total_verified": 5
  },
  "image_evidence": [
    {
      "image_filename": "figure_p4_det_3_007.png",
      "image_path": "FlublokPI/extracted/figures/figure_p4_det_3_007.png",
      "image_type": "Figure",
      "page_number": 4,
      "block_id": "det_3_007",
      "claim_id": "claim_005",
      "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "supports_claim": true,
      "explanation": "A table showing attack rates and relative risks (RR) for PCR-confirmed influenza cases, comparing an IIV4 vaccine group (n/N, % attack rate) against a comparator group. Footnotes define RR, rVE, and identify the comparator as U.S.-licensed standard-dose influenza vaccine, Fluarix Quadrivalent, manufactured by GSK. Evidence: Footnote stating Comparator = U.S.-licensed standard-dose influenza vaccine, Fluarix Quadrivalent, manufactured by GSK, alongside data for IIV4 (quadrivalent) vaccine group. The image shows that in the pivotal trial the IIV4 (quadrivalent) vaccine was evaluated against Fluarix Quadrivalent, which supports the claim. Note: The table header is partially cut off and the brand name \u2018Flublok\u2019 is not explicitly visible, but IIV4 in context refers to the quadrivalent Flublok vaccine.",
      "model_used": "o4-mini",
      "detailed_analysis": {
        "supports_claim": true,
        "image_description": "A table showing attack rates and relative risks (RR) for PCR-confirmed influenza cases, comparing an IIV4 vaccine group (n/N, % attack rate) against a comparator group. Footnotes define RR, rVE, and identify the comparator as U.S.-licensed standard-dose influenza vaccine, Fluarix Quadrivalent, manufactured by GSK.",
        "evidence_found": "Footnote stating Comparator = U.S.-licensed standard-dose influenza vaccine, Fluarix Quadrivalent, manufactured by GSK, alongside data for IIV4 (quadrivalent) vaccine group.",
        "reasoning": "The image shows that in the pivotal trial the IIV4 (quadrivalent) vaccine was evaluated against Fluarix Quadrivalent, which supports the claim.",
        "confidence_notes": "The table header is partially cut off and the brand name \u2018Flublok\u2019 is not explicitly visible, but IIV4 in context refers to the quadrivalent Flublok vaccine."
      }
    }
  ]
}